PropertyValue
?:abstract
  • There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.
?:creator
?:journal
  • ACS_Chem_Neurosci
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19
?:type
?:who_covidence_id
  • #324232
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/2pd5zxfy>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/2pd5zxfy>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all